Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL651924 | 1.00 | MAPT (0.69) | MAPTPKMALDH1A1HTTPOLB | |
| SCHEMBL9122576 | 1.00 | MAPT (0.69) | MAPTPKMALDH1A1HTTPOLB | |
| SCHEMBL6013980 | 0.98 | PKM (0.71) | MAPTPKMALDH1A1HTTPOLB | |
| SCHEMBL8631891 | 0.98 | MAPT (0.67) | MAPTPKMALDH1A1HTTPOLB | |
| SCHEMBL8134887 | 0.98 | MAPT (0.67) | MAPTPKMALDH1A1HTTPOLB | |
| Hydrochloric Acid SCHEMBL3244036 | 0.98 | ALDH1A1 (0.67) | MAPTPKMALDH1A1HTTPOLB | |
| SCHEMBL3977980 | 0.98 | PKM (0.71) | MAPTPKMALDH1A1HTTPOLB | |
| SCHEMBL3419433 | 0.98 | MAPT (0.67) | MAPTPKMALDH1A1HTTPOLB | |
| Bromide SCHEMBL3967182 | 0.96 | MAPT (0.65) | MAPTPKMALDH1A1HTTPOLB | |
| Bromide SCHEMBL3970603 | 0.96 | PKM (0.69) | MAPTPKMALDH1A1HTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004197-A1 | Sulfonamide-based compounds as protein tyrosine kinase inhibitors | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-01-05 | — | — | US | claimed |
| US-20060004197-A1 | Sulfonamide-based compounds as protein tyrosine kinase inhibitors | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004197-A1 | Sulfonamide-based compounds as protein tyrosine kinase inhibitors | SRC, LCK, ABL1 | MAPT 1090/4885PKM 2383/4885ALDH1A1 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.